Hepatitis B virus variants in carriers with hematologic malignancies in whom fulminant hepatic failure develops after chemotherapy

Three patients who were carriers of hepatitis B virus (HBV) and had hematologic malignancies, experienced fulminant hepatic failure after withdrawal of chemotherapy. Before treatment, each patient had inactive HBV infection with undetectable viral DNA polymerase; two patients were negative for hepat...

Full description

Saved in:
Bibliographic Details
Published inInternational hepatology communications Vol. 4; no. 3; pp. 142 - 148
Main Authors Fujise, Kiyotaka, Naito, Yoshihiko, Nakamura, Makoto, Niiya, Minoru, Sato, Shoko, Katayama, Toshio, Watanabe, Reijiro, Hoshina, Sadayori, Kono, Midori, Machida, Katsuhiko
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.09.1995
Subjects
Chemotherapy
Hematologic diseases
Hepatic failure
Hepatitis B virus
Mutation
Hematologic diseases
Hepatic failure
Chemotherapy
Hepatitis B virus
Mutation
Online AccessGet full text

Cover

More Information
Summary:Three patients who were carriers of hepatitis B virus (HBV) and had hematologic malignancies, experienced fulminant hepatic failure after withdrawal of chemotherapy. Before treatment, each patient had inactive HBV infection with undetectable viral DNA polymerase; two patients were negative for hepatitis B e antigen. After chemotherapy, DNA polymerase increased and HBV variants with mutations in the precore region prevailed in their sera. These results implicate precore mutants thriving after chemotherapy and restored immune responses of patients in the pathogenesis of severe hepatic failure.
ISSN:0928-4346
1879-1182
DOI:10.1016/0928-4346(95)00237-5